ATE438408T1 - Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig - Google Patents
Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängigInfo
- Publication number
- ATE438408T1 ATE438408T1 AT00980947T AT00980947T ATE438408T1 AT E438408 T1 ATE438408 T1 AT E438408T1 AT 00980947 T AT00980947 T AT 00980947T AT 00980947 T AT00980947 T AT 00980947T AT E438408 T1 ATE438408 T1 AT E438408T1
- Authority
- AT
- Austria
- Prior art keywords
- hsp
- binding domain
- atp binding
- individual
- independent
- Prior art date
Links
- 102000002812 Heat-Shock Proteins Human genes 0.000 title 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 title 1
- 230000012743 protein tagging Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 230000001939 inductive effect Effects 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000002950 deficient Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17614300P | 2000-01-14 | 2000-01-14 | |
| PCT/US2000/032831 WO2001051081A1 (en) | 2000-01-14 | 2000-12-01 | In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE438408T1 true ATE438408T1 (de) | 2009-08-15 |
Family
ID=22643163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00980947T ATE438408T1 (de) | 2000-01-14 | 2000-12-01 | Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6875435B2 (https=) |
| EP (1) | EP1253939B1 (https=) |
| JP (1) | JP2003519668A (https=) |
| AT (1) | ATE438408T1 (https=) |
| AU (2) | AU1814101A (https=) |
| CA (1) | CA2396384A1 (https=) |
| DE (1) | DE60042704D1 (https=) |
| WO (1) | WO2001051081A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994029459A1 (en) * | 1993-06-04 | 1994-12-22 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
| JP2003519668A (ja) | 2000-01-14 | 2003-06-24 | ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ | 熱ショックタンパク質融合タンパク質による、ｃｄ４＋ｔ細胞非依存性のインビボｃｔｌ惹起による個別ａｔｐ結合ドメインのマッピング |
| CA2404041A1 (en) * | 2000-03-28 | 2001-10-04 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
| US20050267020A1 (en) * | 2001-09-27 | 2005-12-01 | Olivier Faure | Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same |
| WO2003068941A2 (en) * | 2002-02-13 | 2003-08-21 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
| US20090118173A1 (en) * | 2006-01-24 | 2009-05-07 | Universiteit Utrecht Uu Holding B.V. | Treatment and prevention of inflammatory bowel diseases |
| RU2333767C2 (ru) * | 2006-03-31 | 2008-09-20 | Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") | Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции |
| US8742068B2 (en) * | 2007-07-06 | 2014-06-03 | Universiteit Utrecht Holding B.V. | Treatment and prevention of inflammatory diseases and autoimmune diseases |
| EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US20170260286A1 (en) * | 2016-03-10 | 2017-09-14 | The General Hospital Corporation | Antigen-Binding Fusion Proteins with Modified HSP70 Domains |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666847A (en) * | 1981-01-16 | 1987-05-19 | Collaborative Research, Inc. | Recombinant DNA means and method |
| US4557931A (en) | 1982-12-02 | 1985-12-10 | Regents Of The University Of California | Antigenic compositions and methods for using same |
| IE56720B1 (en) | 1983-02-07 | 1991-11-20 | Battelle Memorial Institute | Methods and compositions for expression of competent eukaryotic gene products |
| US4797359A (en) * | 1983-05-10 | 1989-01-10 | Board Of Regents, The University Of Texas System | Heat shock regulated production of selected and fused proteins in yeast |
| GB8404280D0 (en) | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
| IL71683A0 (en) | 1984-04-27 | 1984-09-30 | Yeda Res & Dev | Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria |
| US4918164A (en) * | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
| US4784941A (en) * | 1985-04-08 | 1988-11-15 | Genetic Systems Corporation | Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV |
| AU6713287A (en) | 1986-01-06 | 1987-07-09 | F. Hoffmann-La Roche & Co. | Expression of htlv-iii gag-gene |
| US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
| US4906742A (en) | 1986-07-31 | 1990-03-06 | Whitehead Institute For Biomedical Research | Encoding antigens of M. Leprae |
| NL8701163A (nl) | 1986-09-09 | 1988-04-05 | Nederlanden Staat | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
| WO1988005823A2 (en) | 1987-02-02 | 1988-08-11 | Whitehead Institute For Biomedical Research | Mycobacterium tuberculosis genes encoding protein antigens |
| US4952395A (en) | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| WO1990015873A1 (en) | 1989-06-19 | 1990-12-27 | Whitehead Institute For Biomedical Research | Vector-mediated genomic insertion and expression of dna in bcg |
| US4918166A (en) | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
| US5256767A (en) * | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
| NL8703107A (nl) | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
| US5204259A (en) * | 1988-05-06 | 1993-04-20 | Pharmacia Genetic Engineering, Inc. | Methods and systems for producing HIV antigens |
| WO1989012455A1 (en) | 1988-06-15 | 1989-12-28 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
| WO1994029459A1 (en) | 1993-06-04 | 1994-12-22 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
| US5114844A (en) | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
| WO1990012030A1 (en) | 1989-04-06 | 1990-10-18 | Washington State University Research Foundation, Inc. | Rickettsial antigens for vaccination and diagnosis |
| GB8919321D0 (en) | 1989-08-25 | 1989-10-11 | Univ London | Treatment of chronic inflammatory conditions |
| GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
| GB9024320D0 (en) | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
| CA2095855C (en) | 1990-11-08 | 2003-04-29 | Graham A.W. Rook | Mycobacterium as adjuvant for antigens |
| GB2251186A (en) | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
| EP0521220A1 (en) | 1991-06-14 | 1993-01-07 | Institut Pasteur | Recombinant immunogenic actinomycetale |
| IT1262896B (it) * | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| US5580563A (en) | 1992-05-01 | 1996-12-03 | Tam; James P. | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| ATE303160T1 (de) * | 1993-08-11 | 2005-09-15 | Jenner Technologies | Impfstoff gegen prostatakrebs |
| US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| IL109790A0 (en) | 1994-05-25 | 1994-08-26 | Yeda Res & Dev | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
| GB9419979D0 (en) | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
| WO1997006821A1 (en) | 1995-08-18 | 1997-02-27 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
| US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| WO1997026910A2 (de) * | 1996-01-27 | 1997-07-31 | Max-Delbrück-Centrum für Molekulare Medizin | Tumorimpfstoff für die immuntherapie von malignen tumoren |
| US6455493B1 (en) * | 1996-09-20 | 2002-09-24 | University Of New Mexico | Methods for using heat shock proteins |
| JP4484969B2 (ja) | 1996-11-26 | 2010-06-16 | ヌベンタ バイオファーマスティカル コーポレイション | ストレスタンパク質を含む組成物を使用する免疫応答 |
| CA2282426A1 (en) * | 1997-02-18 | 1998-08-20 | The Whitehead Institute For Biomedical Research | Use of heat shock proteins to deliver moieties into cells |
| KR20060111731A (ko) * | 1997-08-05 | 2006-10-27 | 스트레스젠 바이오테크놀러지스 코포레이션 | 사람 유두종 바이러스 항원과 스트레스 단백질을 포함하는융합 단백질을 포함하는 조성물에 의해 유도된 사람 유두종바이러스 항원에 대한 면역 반응 |
| CA2378097A1 (en) * | 1999-07-08 | 2001-01-18 | Stressgen Biotechnologies Corporation | Induction of a th1-like response in vitro |
| JP2003519668A (ja) * | 2000-01-14 | 2003-06-24 | ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ | 熱ショックタンパク質融合タンパク質による、ｃｄ４＋ｔ細胞非依存性のインビボｃｔｌ惹起による個別ａｔｐ結合ドメインのマッピング |
-
2000
- 2000-12-01 JP JP2001551504A patent/JP2003519668A/ja active Pending
- 2000-12-01 DE DE60042704T patent/DE60042704D1/de not_active Expired - Lifetime
- 2000-12-01 AT AT00980947T patent/ATE438408T1/de not_active IP Right Cessation
- 2000-12-01 CA CA002396384A patent/CA2396384A1/en not_active Abandoned
- 2000-12-01 WO PCT/US2000/032831 patent/WO2001051081A1/en not_active Ceased
- 2000-12-01 AU AU18141/01A patent/AU1814101A/en not_active Abandoned
- 2000-12-01 EP EP00980947A patent/EP1253939B1/en not_active Expired - Lifetime
-
2001
- 2001-01-16 US US09/761,534 patent/US6875435B2/en not_active Expired - Fee Related
-
2004
- 2004-07-01 US US10/885,523 patent/US7501125B2/en not_active Expired - Fee Related
-
2006
- 2006-03-17 AU AU2006201114A patent/AU2006201114B2/en not_active Ceased
-
2009
- 2009-03-09 US US12/400,774 patent/US20100040645A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6875435B2 (en) | 2005-04-05 |
| DE60042704D1 (de) | 2009-09-17 |
| US7501125B2 (en) | 2009-03-10 |
| US20100040645A1 (en) | 2010-02-18 |
| US20050048079A1 (en) | 2005-03-03 |
| EP1253939B1 (en) | 2009-08-05 |
| AU2006201114B2 (en) | 2008-10-23 |
| AU2006201114A1 (en) | 2006-04-13 |
| US20020146426A1 (en) | 2002-10-10 |
| WO2001051081A1 (en) | 2001-07-19 |
| AU1814101A (en) | 2001-07-24 |
| JP2003519668A (ja) | 2003-06-24 |
| EP1253939A1 (en) | 2002-11-06 |
| CA2396384A1 (en) | 2001-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE438408T1 (de) | Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig | |
| DE60025832D1 (de) | Mehrere zytokin-antikörper komplexen | |
| ATE490969T1 (de) | Modifizierte transferrin-fusionsproteine | |
| DE60333306D1 (de) | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen | |
| WO2001093913A3 (en) | T cell receptor fusions and conjugates and methods of use thereof | |
| PT724456E (pt) | Anticorpos contra cd4 | |
| WO2004084805A3 (en) | Acetylated tat polypeptides and methods of use thereof | |
| EP1071460A4 (en) | INTERNALIZING ERB2 ANTIBODIES | |
| WO2004020404A3 (en) | Modified transferin-antibody fusion proteins | |
| WO2003007889A3 (en) | Therapeutic agents comprising pro-apoptotic proteins | |
| ATE555202T1 (de) | Verfahren zur lieferung von rna-interferenz und verwendungen damit | |
| EP0687183A4 (en) | SYNERGISTIC COMPOSITION CONSISTING OF A CD4-BASED PROTEIN AND ANTI-HIV-1 ANTIBODY, AND METHODS FOR THE USE THEREOF | |
| CA2345903A1 (en) | Molecular pathogenicide mediated plant disease resistance | |
| WO2001059094A3 (en) | Method of regulating transcription in a cell by altering remodeling of cromatin | |
| EA200000331A1 (ru) | Фармацевтические композиции, содержащие белок плазмы | |
| DE69406423D1 (de) | Methode zum überbringen von agenzien an zielzellen | |
| NO932672L (no) | Monokloane antistoffer mot elam-1 og anvendelser derav | |
| DE69736995D1 (de) | Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle | |
| ATE450544T1 (de) | Streptavidin-bindungspeptid | |
| WO2002042422A3 (en) | Molecular interactions in hematopoietic cells | |
| WO2004108885A3 (en) | Fc chimeric proteins with anti-hiv drugs | |
| WO2001094949A3 (en) | Soluble cd1 compositions and uses thereof | |
| AU2003288229A1 (en) | Mixture of at least two fusion proteins, the production thereof and the use of the same | |
| ATE452650T1 (de) | Transferrin-fusionsproteinbibliotheken | |
| WO2002031512A3 (en) | Molecular interactions in hematopoietic cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |